Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028

Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028

  • Pages: 119
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Mar, 2019
  • SKU: DIMI0504
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Prader-Willi Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Prader-Willi Syndrome (PWS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2017-2028

Prader-Willi Syndrome - Disease Understanding
According to US National Library of Medicine, Prader-Willi Syndrome (PWS) is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes).
People with Prader-Willi Syndrome typically have mild to moderate intellectual impairment and learning disabilities. Behavioral problems are common, including temper outbursts, stubbornness, and compulsive behavior such as picking at the skin. Sleep abnormalities can also occur. Additional features of this condition include distinctive facial features such as a narrow forehead, almond-shaped eyes, and a triangular mouth; short stature; and small hands and feet. Some people with Prader-Willi syndrome have unusually fair skin and light-colored hair. Both affected males and affected females have underdeveloped genitals. Puberty is delayed or incomplete, and most affected individuals are unable to have children (infertile).
The DelveInsight Prader-Willi Syndrome (PWS) market report gives a thorough understanding of the Prader-Willi Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Prader-Willi Syndrome in the US, Europe, and Japan.

Prader-Willi Syndrome Epidemiology
The Prader-Willi Syndrome (PWS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by diagnosed prevalent population, mutation-specific prevalent population and prevalent population of Prader-Willi Syndrome by clinical manifestations.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Prader-Willi Syndrome was estimated to be 47,560 [7MM] in 2018. United States accounts for the highest Prader-Willi cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest prevalent patient population of Prader-Willi Syndrome, followed by Italy.

Prader-Willi Syndrome Drug Chapters
This segment of the Prader-Willi Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, pharmacological management of Prader-Willi Syndrome focuses largely on the use of human growth hormone (HGH) supplementation which is approved in the US. Growth hormone supplementation constitutes the primary component of the entire therapeutic market composition due to the nearly ubiquitous deficiency of growth hormone (GH) in PWS patients. Some of the majorly approved GH therapies include Pfizer’s Genotropin (somatropin) along with other major brands such as Norditropin (Novo Nordisk) and a few others in the US. Central nervous system and cardiovascular agents are used with increasing frequency in older PWS patients. Another approved drug is Omnitrope (somatropin [rDNA origin] injection) from Sandoz. Detailed chapters for all of these drug therapies have been covered in the report.

Prader-Willi Syndrome Market Outlook
The Prader-Willi Syndrome (PWS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Prader-Willi Syndrome (PWS) was estimated to be USD 2110.17 million in 2018. The United States accounts for the largest market size of Prader-Willi Syndrome, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Amongst the therapeutic class, Hormone Therapies hold the highest patient share [%] amongst the other therapeutic options available for the treatment of PWS. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
 

Prader-Willi Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Upcoming therapies, such as DCCR (Soleno Therapeutics), LV-101 (Levo Therapeutics) and Lariglutide (Novo Nordisk), have the potential to create a positive shift in the PWS market size during the study period (2017-2028). Expected launch of potential therapies will lead to an increase in the market size of Prader-Willi Syndrome (PWS) in the coming years. DCCR (Soleno Therapeutics) is the going to be the first FDA approved therapy that is expected to be launched in all of the 7 Major Markets, during the forecast period [2018-2028].
 

Prader-Willi Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Prader-Willi Syndrome Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Prader-Willi Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Prader-Willi Syndrome market.
  • Organize sales and marketing efforts by identifying the best opportunities for Prader-Willi Syndrome market.
  • To understand the future market competition in the Prader-Willi Syndrome market.

1 Key Insights
2 Prader-Willi Syndrome Market Overview at a Glance
2.1 Market Share (%) Distribution of Prader-Willi Syndrome in 2017
2.2 Market Share (%) Distribution of Prader-Willi Syndrome in 2028
3 Prader-Willi syndrome: Disease Background and Overview
3.1 Introduction
3.2 Cause
3.3 Symptoms
3.4 Complications
3.5 Stages of Prader-Willi Syndrome
3.6 Molecular Genetic Pathogenesis
3.7 Diagnosis
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Population and Forecast Parameters
4.3 Total Prevalence of Prader-Willi Syndrome in 7MM
5 Country Wise-Epidemiology of Prader-Willi Syndrome
6 United States
6.1 Assumptions and Rationale
6.2 Prevalent Population of Prader-Willi Syndrome (PWS) in the United States
6.3 Diagnosed cases of PWS in the US
6.4 PWS cases by Mutation Types in the US
6.5 PWS associated Clinical Manifestations
7 EU-5
7.1 Assumptions and Rationale
8 Germany
8.1 Prevalent Population of Prader-Willi Syndrome (PWS) in Germany
8.2 Diagnosed cases of PWS in Germany
8.3 PWS cases by Mutation Types in Germany
8.4 PWS associated Clinical Manifestations
9 France
9.1 Prevalent Population of Prader-Willi Syndrome (PWS) in France
9.2 Diagnosed cases of PWS in France
9.3 PWS cases by Mutation Types in France
9.4 PWS associated Clinical Manifestations
10 Italy
10.1 Prevalent Population of Prader-Willi Syndrome (PWS) in Italy
10.2 Diagnosed cases of PWS in Italy
10.3 PWS cases by Mutation Types in Italy
10.4 PWS associated Clinical Manifestations
11 Spain
11.1 Prevalent Population of Prader-Willi Syndrome (PWS) in Spain
11.2 Diagnosed cases of PWS in Spain
11.3 PWS cases by Mutation Types in Spain
11.4 PWS associated Clinical Manifestations
12 United Kingdom
12.1 Prevalent Population of Prader-Willi Syndrome (PWS) in United Kingdom
12.2 Diagnosed cases of PWS in United Kingdom
12.3 PWS cases by Mutation Types in United Kingdom
12.4 PWS associated Clinical Manifestations
13 Japan
13.1 Assumptions and Rationale
13.2 Prevalent Population of Prader-Willi Syndrome (PWS) in Japan
13.3 Diagnosed cases of PWS in Japan
13.4 PWS cases by Mutation Types in Japan
13.5 PWS associated Clinical Manifestations
14 Treatment
14.1.1 Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
15 Unmet Needs
16 Marketed Drugs
16.1 GENOTROPIN: Pfizer
16.1.1 Product Description
16.1.2 Advantages & Disadvantages
16.1.3 Safety and Efficacy
16.1.4 Product Profile
16.2 Other Hormonal Therapies
16.2.1 OMNITROPE: Sandoz Inc
16.3 Norditropin: Novo Nordisk
16.3.1 Product Description
16.3.2 Other development activities
16.3.3 Safety and Efficacy
16.3.4 Product Profile
17 Emerging Drugs Analysis
18 Emerging Therapies
18.1 Diazoxide Choline Controlled-Release: Soleno Therapeutics
18.1.1 Product Description
18.1.2 Other development activities
18.1.3 Clinical Development
18.1.4 Safety and Efficacy
18.1.5 Product Profile
18.2 LV-101: Levo Therapeutics
18.2.1 Product Description
18.2.2 Other development activities
18.2.3 Clinical Development
18.2.4 Safety and Efficacy
18.2.5 Product Profile
18.3 Liraglutide: Novo Nordisk
18.3.1 Product Description
18.3.2 Clinical Development
18.3.3 Product Profile
18.2 Other Promising Candidates
18.3 Livoletide: Millendo Therapeutics
18.3.1 Product Description
18.3.2 Other development activities
18.3.3 Clinical Development
18.3.4 Safety and Efficacy
18.3.5 Product Profile
19 Prader-Willi Syndrome: 7 Major Market Analysis
19.1 Key Findings
19.2 Total Market Size of Prader-Willi Syndrome in 7MM
19.3 7 MM Size of Prader-Willi Syndrome by Therapies
20 Market Outlook by Country
20.1 The United States: Market Outlook
20.2 United States Market Size
20.2.1 Total Market size of PWS
20.2.2 PWS Market Size by Therapies
20.3 EU-5 Countries: Market Outlook
20.4 Germany Market Size
20.4.1 Total Market Size of PWS
20.4.2 PWS Market Size by Therapies
20.5 France Market Size
20.5.1 Total Market Size of PWS
20.5.2 PWS Market Size by Therapies
20.6 Italy Market Size
20.6.1 Total Market Size of PWS
20.6.2 PWS Market Size by Therapies
20.7 Spain Market Size
20.7.1 Total Market size of PWS
20.7.2 PWS Market Size by Therapies
20.8 The United Kingdom Market Size
20.8.1 Total Market Size of PWS
20.8.2 PWS Market Size by Therapies
20.9 Japan: Market Outlook
20.1 Japan: Market Size
20.10.1 Total Market Size of PWS
20.10.2 PWS Market Size by Therapies
21 Market Drivers
22 Market Barriers
23 Appendix
24 Report Methodology
24.1 Sources Used
25 DelveInsight Capabilities
26 Disclaimer
27 About DelveInsight

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Table 1:  Total Prevalent Population of Prader-Willi Syndrome in 7MM (2017-2028)
Table 2:  Prevalent Population of PWS in the United States (2017-2028)
Table 3:  Diagnosed cases of PWS in the United States (2017-2028)
Table 4:   Prevalence of PWS by mutation types in the US (2017-2028)
Table 5:  PWS associated Clinical Manifestations in the United States (2017-2028)
Table 6:  Prevalent Population of PWS in Germany (2017-2028)
Table 7:  Diagnosed cases of PWS in Germany (2017-2028)
Table 8:   Prevalence of PWS by mutation types in Germany (2017-2028)
Table 9:  PWS associated Clinical Manifestations in Germany (2017-2028)
Table 10:  Prevalent Population of PWS in France (2017-2028)
Table 11:  Diagnosed cases of PWS in France (2017-2028)
Table 12:   Prevalence of PWS by mutation types in France (2017-2028)
Table 13:  PWS associated Clinical Manifestations in France (2017-2028)
Table 14:  Prevalent Population of PWS in Italy (2017-2028)
Table 15:  Diagnosed cases of PWS in Italy (2017-2028)
Table 16:   Prevalence of PWS by mutation types in Italy (2017-2028)
Table 17:  PWS associated Clinical Manifestations in Italy (2017-2028)
Table 18:  Prevalent Population of PWS in Spain (2017-2028)
Table 19:  Diagnosed cases of PWS in Spain (2017-2028)
Table 20:   Prevalence of PWS by mutation types  in Spain (2017-2028)
Table 21:  PWS associated Clinical Manifestations in Spain (2017-2028)
Table 22:  Prevalent Population of PWS in United Kingdom (2017-2028)
Table 23:  Diagnosed cases of PWS in the United Kingdom (2017-2028)
Table 24:   Prevalence of PWS by mutation types  in United Kingdom (2017-2028)
Table 25:  PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Table 26:  Prevalent Population of PWS in Japan (2017-2028)
Table 27:  Diagnosed cases of PWS in Japan (2017-2028)
Table 28:   Prevalence of PWS by mutation types in Japan (2017-2028)
Table 29:  PWS associated Clinical Manifestations in Japan (2017-2028)
Table 30: Comparison of Emerging drugs
Table 31: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019
Table 32: LV-101 Clinical Trial Description, 2019
Table 33: liraglutide Clinical Trial Description, 2018
Table 34: Livoletide Clinical Trial Description, 2018
Table 35:  7 Major Market Size of PWS in USD Million (2017-2028)
Table 36: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Table 37: The US Market Prader-Willi Syndrome in USD Million (2017-2028)
Table 38: The US PWS Market Size by Therapies in USD Million (2017-2028)
Table 39:  Market Size of PWS in Germany, USD Millions (2017-2028)
Table 40: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Table 41:  Market Size of PWS in France, USD Millions (2017-2028)
Table 42: France PWS Market Size by Therapies in USD Million (2017-2028)
Table 43:  Market Size of PWS in Italy, USD Millions (2017-2028)
Table 44: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Table 45:  Market Size of PWS in Spain, USD Millions (2017-2028)
Table 46: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Table 47:  Market Size of PWS in UK, USD Millions (2017-2028)
Table 48: UK PWS Market Size by Therapies in USD Million (2017-2028)
Table 49:  Market Size of PWS in Japan, USD Millions (2017-2028)
Table 50:Japan PWS Market Size by Therapies in USD Million (2017-2028)

Figure 1: Mechanism of obesity in Prader–Willi syndrome
Figure 2: Molecular testing strategy for Prader-Willi Syndrome
Figure 3: Total Prevalent Population of Prader-Willi Syndrome in 7 MM (2017-2028)
Figure 4: Prevalent Population of PWS in the United States (2017-2028)
Figure 5: Diagnosed cases of PWS in the US (2017-2028)
Figure 6: PWS associated Clinical Manifestations in the United States (2017-2028)
Figure 7: Diagnosed cases of PWS in the United States (2017-2028)
Figure 8: Prevalent Population of PWS in Germany (2017-2028)
Figure 9: Diagnosed cases of PWS in Germany (2017-2028)
Figure 10: PWS associated Clinical Manifestations in Germany (2017-2028)
Figure 11: Diagnosed cases of PWS in Germany (2017-2028)
Figure 12: Prevalent Population of PWS in France (2017-2028)
Figure 13: Diagnosed cases of PWS in France (2017-2028)
Figure 14: Prevalence of PWS by Mutation Types in France (2017-2028)
Figure 15: PWS associated Clinical Manifestations in France (2017-2028)
Figure 16: Prevalent Population of PWS in Italy (2017-2028)
Figure 17: Diagnosed cases of PWS in Italy (2017-2028)
Figure 18: Prevalence of PWS by Mutation Types in Italy (2017-2028)
Figure 19: PWS associated Clinical Manifestations in Italy (2017-2028)
Figure 20: Prevalent Population of PWS in Spain (2017-2028)
Figure 21: Diagnosed cases of PWS in Spain (2017-2028)
Figure 22: Prevalence of PWS by Mutation Types in Spain (2017-2028)
Figure 23: PWS associated Clinical Manifestations in the Spain (2017-2028)
Figure 24: Prevalent Population of PWS in United Kingdom (2017-2028)
Figure 25: Diagnosed cases of PWS in United Kingdom (2017-2028)
Figure 26: Prevalence of PWS by Mutation Types in United Kingdom (2017-2028)
Figure 27: PWS associated Clinical Manifestations in United Kingdom (2017-2028)
Figure 28: Prevalent Population of PWS in Japan (2017-2028)
Figure 29: Diagnosed cases of PWS in Japan (2017-2028)
Figure 30: Prevalence of PWS by Mutation Types in Japan (2017-2028)
Figure 31: PWS associated Clinical Manifestations in Japan (2017-2028)
Figure 32: Unmet Needs for PWS
Figure 33: 7 Major Market Size of PWS in USD Million (2017-2028)
Figure 34: 7 Major Market Size of PWS by Therapies in USD Million (2017-2028)
Figure 35: Market Size of Prader-Willi Syndrome in the United States, USD Millions (2017-2028)
Figure 36: The U.S. PWS Market Size by Therapies in USD Million (2017-2028)
Figure 37: Market Size of PWS in Germany, USD Millions (2017-2028)
Figure 38: Germany PWS Market Size by Therapies in USD Million (2017-2028)
Figure 39: Market Size of PWS in France, USD Millions (2017-2028)
Figure 40: France PWS Market Size by Therapies in USD Million (2017-2028)
Figure 41: Market Size of PWS in Italy, USD Millions (2017-2028)
Figure 42: Italy PWS Market Size by Therapies in USD Million (2017-2028)
Figure 43: Market Size of PWS in Spain, USD Millions (2017-2028)
Figure 44: Spain PWS Market Size by Therapies in USD Million (2017-2028)
Figure 45: Market Size of PWS in UK, USD Millions (2017-2028)
Figure 46: UK PWS Market Size by Therapies in USD Million (2017-2028)
Figure 47: Market Size of PWS in Japan, USD Millions (2017-2028)
Figure 48: Japan PWS Market Size by Therapies in USD Million (2017-2028)
Figure 49: Market Drivers of Prader-Willi Syndrome
Figure 50:Market Barriers of  Prader-Willi Syndrome (PWS)

Key Companies

Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.